Learn About Polymicrogyria

What is the definition of Polymicrogyria?

Polymicrogyria is a condition characterized by abnormal development of the brain before birth. The surface of the brain normally has many ridges or folds, called gyri. In people with polymicrogyria, the brain develops too many folds, and the folds are unusually small. The name of this condition literally means too many (poly-) small (micro-) folds (-gyria) in the surface of the brain.

What are the causes of Polymicrogyria?

In most people with polymicrogyria, the cause of the condition is unknown. However, researchers have identified several environmental and genetic factors that can be responsible for the disorder. Environmental causes of polymicrogyria include certain infections during pregnancy and a lack of oxygen to the fetus (intrauterine ischemia).

How prevalent is Polymicrogyria?

The prevalence of isolated polymicrogyria is unknown. Researchers believe that it may be relatively common overall, although the individual forms of the disorder (such as bilateral generalized polymicrogyria) are probably rare.

Is Polymicrogyria an inherited disorder?

Isolated polymicrogyria can have different inheritance patterns. Several forms of the condition, including bilateral frontoparietal polymicrogyria (which is associated with mutations in the ADGRG1 gene), have an autosomal recessive pattern of inheritance. In autosomal recessive inheritance, both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Who are the top Polymicrogyria Local Doctors?
Elite in Polymicrogyria
Medical Genetics | Pediatrics | Pediatric Neurology
Elite in Polymicrogyria
Medical Genetics | Pediatrics | Pediatric Neurology

Fairview Express Care

2450 Riverside Ave, 
Minneapolis, MN 
Experience:
47+ years
Languages Spoken:
English
Accepting New Patients

William Dobyns is a Medical Genetics specialist and a Pediatrics provider in Minneapolis, Minnesota. Dr. Dobyns has been practicing medicine for over 47 years and is rated as an Elite provider by MediFind in the treatment of Polymicrogyria. His top areas of expertise are Increased Head Circumference, Polymicrogyria, Lissencephaly, and Cerebellar Hypoplasia. Dr. Dobyns is currently accepting new patients.

Elite in Polymicrogyria
Elite in Polymicrogyria
Brussels, BRU, BE 

Dina Amrom practices in Brussels, Belgium. Ms. Amrom and is rated as an Elite expert by MediFind in the treatment of Polymicrogyria. Her top areas of expertise are Polymicrogyria, Rasmussen Encephalitis, Subcortical Band Heterotopia, and Miller-Dieker Syndrome.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Polymicrogyria
Pediatric Neurology | Neurology
Elite in Polymicrogyria
Pediatric Neurology | Neurology
300 Longwood Ave, Children's Hospital Boston, 
Boston, MA 
Languages Spoken:
English
Accepting New Patients

Annapurna Poduri is a Pediatric Neurologist and a Neurologist in Boston, Massachusetts. Dr. Poduri and is rated as an Elite provider by MediFind in the treatment of Polymicrogyria. Her top areas of expertise are West Syndrome, Epilepsy, Spasmus Nutans, and Polymicrogyria. Dr. Poduri is currently accepting new patients.

What are the latest Polymicrogyria Clinical Trials?
A Phase II Double-blind Multi-center, Placebo-controlled Trial, to Assess the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP)

Summary: This study is a two periods multi-center Phase II trial, with a 6 months double-blind, placebo-controlled period followed by open label period, to assess the efficacy and safety of alpelisib (BYL719) in pediatric and adult patients with Megalencephaly-CApillary malformation Polymicrogyria syndrome (MCAP)

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

Summary: This is a 3-part Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, RLY-2608, in adults and children with PIK3CA Related Overgrowth Spectrum (PROS) and malformations driven by PIK3CA mutation. Part 1 is a dose selection, Part 2 is a basket design with exploratory single-arm cohorts for various subpopulations of participants, and Part 3 is randomize...

Who are the sources who wrote this article ?

Published Date: June 01, 2009
Published By: National Institutes of Health